OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

著者: Mark E. Robson, Nadine Tung, PierFranco Conte, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Norikazu Masuda, Suzette Delaloge, W. Li, Anne Armstrong, Weiwen Wu, Carsten Goessl, Sarah Runswick, Susan M. Domchek - Annals of Oncology 2019 被引用: 760